GBA1 and synucleinopathy: Here, we have implemented a gene therapy strategy to enhance GCase activity in mice and nonhuman primate (NHP) models of PD-like synucleinopathy by taking advantage of the intraparenchymal focused delivery into the substantia nigra pars compacta (SNpc) of rAAVs coding for the GBA1 gene.